G Mani Subramanian

Summary

Affiliation: Human Genome Sciences
Country: USA

Publications

  1. ncbi request reprint A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers
    G Mani Subramanian
    Human Genome Sciences, Rockville, MD 20850, USA
    Clin Infect Dis 41:12-20. 2005
  2. doi request reprint Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus
    G Mani Subramanian
    Human Genome Sciences, Inc, Rockville, MD 20850, USA
    Chemotherapy 54:176-80. 2008
  3. ncbi request reprint Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C
    G Mani Subramanian
    Human Genome Sciences, Inc, 14200 Shady Grove Road, Rockville, Maryland 21042, USA
    Nat Biotechnol 25:1411-9. 2007
  4. doi request reprint Raxibacumab for the treatment of inhalational anthrax
    Thi Sau Migone
    Human Genome Sciences, Rockville, MD 20850, USA
    N Engl J Med 361:135-44. 2009
  5. doi request reprint Population pharmacokinetics and exposure-response of albinterferon alfa-2b
    Matthew M Riggs
    Metrum Research Group LLC, Tariffville, CT, USA
    J Clin Pharmacol 52:475-86. 2012
  6. ncbi request reprint Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:901-8. 2006
  7. doi request reprint Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients
    Vincent G Bain
    University of Alberta, Edmonton, Canada
    Clin Gastroenterol Hepatol 6:701-6. 2008
  8. ncbi request reprint A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:35-45. 2006
  9. doi request reprint Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C
    Stefan Zeuzem
    JW Goethe University Hospital, Frankfurt, Germany
    Hepatology 48:407-17. 2008
  10. ncbi request reprint A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients
    Vincent G Bain
    University of Alberta, Liver Unit, Zeidler Ledcor Center, 130 University Campus, Edmonton, Alberta, Canada, T6G 2X8
    J Hepatol 44:671-8. 2006

Collaborators

Detail Information

Publications11

  1. ncbi request reprint A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers
    G Mani Subramanian
    Human Genome Sciences, Rockville, MD 20850, USA
    Clin Infect Dis 41:12-20. 2005
    ..A fully human monoclonal antibody against B. anthracis PA, PAmAb, was previously shown to provide a survival advantage in rabbit and monkey models of inhalational anthrax...
  2. doi request reprint Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus
    G Mani Subramanian
    Human Genome Sciences, Inc, Rockville, MD 20850, USA
    Chemotherapy 54:176-80. 2008
    ..The type 1 interferons (INF-alpha and INF-beta) are potent antiviral agents. Albumin-INF-alpha and albumin-INF-beta are novel recombinant proteins consisting of IFN-alpha or IFN-beta genetically fused to human albumin...
  3. ncbi request reprint Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C
    G Mani Subramanian
    Human Genome Sciences, Inc, 14200 Shady Grove Road, Rockville, Maryland 21042, USA
    Nat Biotechnol 25:1411-9. 2007
    ..These fusion proteins, which are at present in different phases of clinical development, might lead to improved therapies across a broad range of diseases...
  4. doi request reprint Raxibacumab for the treatment of inhalational anthrax
    Thi Sau Migone
    Human Genome Sciences, Rockville, MD 20850, USA
    N Engl J Med 361:135-44. 2009
    ..Raxibacumab is a human IgG1lambda monoclonal antibody directed against protective antigen, a component of the anthrax toxin...
  5. doi request reprint Population pharmacokinetics and exposure-response of albinterferon alfa-2b
    Matthew M Riggs
    Metrum Research Group LLC, Tariffville, CT, USA
    J Clin Pharmacol 52:475-86. 2012
    ..Given the lack of consistent efficacy/safety exposure-response relationships, further investigation is necessary to optimize albIFN dosing...
  6. ncbi request reprint Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:901-8. 2006
    ..05). In conclusion, alb-IFN demonstrated robust induction of ISG that was consistent with the response associated with an IFN-alpha...
  7. doi request reprint Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients
    Vincent G Bain
    University of Alberta, Edmonton, Canada
    Clin Gastroenterol Hepatol 6:701-6. 2008
    ..A phase 2, randomized, multicenter, open-label study evaluated the safety and efficacy of albinterferon alfa-2b in interferon-alpha treatment-naïve patients with genotype 2/3, chronic hepatitis C virus infection...
  8. ncbi request reprint A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:35-45. 2006
    ..These results support further clinical studies of albumin-IFN-alpha for the treatment of patients with chronic hepatitis C...
  9. doi request reprint Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C
    Stefan Zeuzem
    JW Goethe University Hospital, Frankfurt, Germany
    Hepatology 48:407-17. 2008
    ..At week 12, mean treatment-associated missed workdays were significantly lower with alb-IFN 900 mug q2wk versus PEG-IFNalpha-2a (1.1 versus 4.3 days; P = 0.006)...
  10. ncbi request reprint A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients
    Vincent G Bain
    University of Alberta, Liver Unit, Zeidler Ledcor Center, 130 University Campus, Edmonton, Alberta, Canada, T6G 2X8
    J Hepatol 44:671-8. 2006
    ..Recombinant human albumin-interferon alfa (alb-IFN) is a novel 85.7-kD recombinant protein consisting of interferon alfa-2b genetically fused to human serum albumin...
  11. doi request reprint Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients
    Jacob Lalezari
    Quest Clinical Research, San Francisco, CA 94115, USA
    J Infect Dis 197:721-7. 2008
    ..HGS004 is a fully human immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5) with robust in vitro activity against a diverse panel of CCR5-tropic human immunodeficiency virus type 1 (HIV-1) isolates...